MEDICINOVA INC (MNOV) Stock Price, Forecast & Analysis
NASDAQ:MNOV • US58468P2065
MNOV Key Statistics, Chart & Performance
The current stock price of MNOV is 1.48 USD. In the past month the price decreased by -28.19%. In the past year, price decreased by -17.68%.
MNOV Technical Analysis
MNOV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNOV. While MNOV has a great health rating, there are worries on its profitability.
MNOV Financial Highlights
Over the last trailing twelve months MNOV reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -19.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.22% | ||
| ROE | -25.13% | ||
| Debt/Equity | 0 |
MNOV Forecast & Estimates
7 analysts have analysed MNOV and the average price target is 9.18 USD. This implies a price increase of 520.27% is expected in the next year compared to the current price of 1.48.
MNOV Ownership
MNOV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.88 | 403.74B | ||
| AMGN | AMGEN INC | 16.96 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.5 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.72 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.71 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.62 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNOV
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Company Info
MEDICINOVA INC
4275 Executive Square, Suite 300
La Jolla CALIFORNIA 92037 US
CEO: Yuichi Iwaki
Employees: 13
Phone: 18583731500
MEDICINOVA INC / MNOV FAQ
What does MEDICINOVA INC do?
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
What is the stock price of MEDICINOVA INC today?
The current stock price of MNOV is 1.48 USD. The price increased by 9.63% in the last trading session.
What is the dividend status of MEDICINOVA INC?
MNOV does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNOV stock?
MNOV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of MEDICINOVA INC (MNOV) based on its PE ratio?
MEDICINOVA INC (MNOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the market capitalization of MNOV stock?
MEDICINOVA INC (MNOV) has a market capitalization of 72.74M USD. This makes MNOV a Micro Cap stock.
Who owns MEDICINOVA INC?
You can find the ownership structure of MEDICINOVA INC (MNOV) on the Ownership tab.